1. Short summary / abstract
An update of the IDSA guidelines 2000 for Community-acquired pneumonia taking new developments and problems into account.
Updated sections: initial site of treatment, diagnosis of C. pneumoniae, Legionaires disease, bioterrorism, prevention, macrolides, fluoroquinolone resistance and performance indicators.
New sections: pneumococcal antigen, breakpoints for cefotaxime and ceftriaxone, SARS, treatment of bacteraemic pneumococcal pneumonia, viral CAP, CAP in the elderly and ketolides.
2. What question is the document addressing?
What new developments are there in the management of CAP?
3. Type of study
4. Methods valid & appropriate?
Methods of search and evaluation are not specified.
5. Results / recommendations reliable?
All recommendations are graded by United States Public Health Service grading system for rating recommendations in clinical guidelines. There is also a referenced commentary stating the evidence.
6. Any major problems and biases?
Some patient management recommendations are not applicable to the UK due to differences in the USA healthcare system.
7. Any other important / relevant studies which confirm or contradict?
Should be used in conjunction with ‘Practice Guidelines for the Management of Community-Acquired Pneumonia in Adults’ John G. Bartlett, Scott F. Dowell, Lionel A. Mandell, Thomas M. File, Jr., Daniel M. Musher, and Michael J. Fine
Clinical Infectious Diseases 2000;31:347-82
British Thoracic Society Guidelines for the Management of Community Acquired Pneumonia in Adults can be found in Thorax 2001;56(suppl IV):1-64.
*** Note: These are the views of a professional expert rather than an official statement from his or her society, organisation or advisory committee.
(Society / Organisation / Advisory Committee):
|City Hospital, Birmingham and a member of BSAC|